Fairmount Healthcare Fund II L.P.'s Form 4 filing
Viridian Therapeutics, Inc.DEVRDN · filed Sep 17, 2024
- Accession no.
- 0001104659-24-100769
- Filed
- Sep 17, 2024, 9:00 PM ET
- Trade date
- Sep 13, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $30.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fairmount Healthcare Fund II L.P.CIK 0001769651 | Director, 10% Owner |
| Fairmount Funds Management LLCCIK 0001802528 | Director, 10% Owner |
| Fairmount Healthcare Fund II GP LLCCIK 0001830382 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2024 | Common Stock | PPurchaseAcquired | +1,600,000 | $18.75 | +$30,000,000 | 3,445,813 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount Funds Management LLC.